Name (Synonyms) | Correlation | |
---|---|---|
drug2030 | Rarefaction Wiki | 0.28 |
drug776 | Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care Wiki | 0.28 |
drug55 | ACEI Wiki | 0.28 |
drug508 | Calcium Channel Blockers Wiki | 0.28 |
drug56 | ACEI/ARB Wiki | 0.28 |
drug176 | Angiotensin receptor blocker Wiki | 0.28 |
drug2486 | The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: Wiki | 0.28 |
drug1627 | Non-ACEI/ARB Wiki | 0.28 |
drug2507 | Thiazide or Thiazide-like diuretics Wiki | 0.28 |
drug1752 | PWV Wiki | 0.28 |
drug49 | ABPM Wiki | 0.28 |
drug175 | Angiotensin converting enzyme inhibitor Wiki | 0.28 |
drug582 | Clinical data Wiki | 0.28 |
drug849 | Enhanced Chronic Disease Self-management program Wiki | 0.28 |
drug760 | Diagnostic test for SARS-Cov2 for patients and health staff Wiki | 0.28 |
drug644 | Control-EDI Wiki | 0.28 |
drug1242 | Intervention-EDI and health coaching Wiki | 0.28 |
drug914 | FMD Wiki | 0.28 |
drug691 | Cyclosporine Wiki | 0.20 |
drug804 | ECG Wiki | 0.20 |
drug76 | ARB Wiki | 0.20 |
drug2121 | SAB-185 Wiki | 0.20 |
drug53 | ACE inhibitor Wiki | 0.16 |
drug1645 | Normal saline Wiki | 0.12 |
drug698 | DAS181 Wiki | 0.11 |
drug315 | Baricitinib Wiki | 0.10 |
drug2326 | Standard of care Wiki | 0.06 |
drug1822 | Placebo Wiki | 0.02 |
Name (Synonyms) | Correlation | |
---|---|---|
D006973 | Hypertension NIH | 1.00 |
D001997 | Bronchopulmonary Dysplasia NIH | 0.28 |
D008595 | Menorrhagia NIH | 0.28 |
D006929 | Hyperaldosteronism NIH | 0.28 |
D014552 | Urinary Tract Infections NIH | 0.28 |
D054559 | Hyperphosphatemia NIH | 0.28 |
D006976 | Hypertension, Pulmonary NIH | 0.28 |
D004314 | Down Syndrome NIH | 0.28 |
D000309 | Adrenal Insufficiency NIH | 0.28 |
D007008 | Hypokalemia NIH | 0.28 |
D009080 | Mucocutaneous Lymph Node Syndrome NIH | 0.20 |
D006470 | Hemorrhage NIH | 0.20 |
D002908 | Chronic Disease NIH | 0.18 |
D051436 | Renal Insufficiency, Chronic NIH | 0.16 |
D001289 | Attention Deficit Disorder with Hyperactivity NIH | 0.14 |
D007674 | Kidney Diseases NIH | 0.12 |
D002318 | Cardiovascular Diseases NIH | 0.12 |
D020141 | Hemostatic Disorders NIH | 0.08 |
D001778 | Blood Coagulation Disorders NIH | 0.08 |
D004194 | Disease NIH | 0.05 |
D013577 | Syndrome NIH | 0.03 |
D003141 | Communicable Diseases NIH | 0.02 |
D018352 | Coronavirus Infections NIH | 0.02 |
D007239 | Infection NIH | 0.02 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.01 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0002905 | Hyperphosphatemia HPO | 0.28 |
HP:0002900 | Hypokalemia HPO | 0.28 |
HP:0000846 | Adrenal insufficiency HPO | 0.28 |
HP:0000132 | Menorrhagia HPO | 0.28 |
HP:0002092 | Pulmonary arterial hypertension HPO | 0.28 |
HP:0000859 | Hyperaldosteronism HPO | 0.28 |
HP:0012622 | Chronic kidney disease HPO | 0.16 |
HP:0007018 | Attention deficit hyperactivity disorder HPO | 0.14 |
HP:0000077 | Abnormality of the kidney HPO | 0.12 |
HP:0001626 | Abnormality of the cardiovascular system HPO | 0.12 |
HP:0001928 | Abnormality of coagulation HPO | 0.08 |
There are 13 clinical trials
Chronic kidney disease (CKD) is a serious and growing public health problem. The purpose of this study is to find out if an educational worksheet, called the Encounter Decision Intervention (EDI), combined with health coaching helps CKD patients improve their blood pressure and other health outcomes. The research team hypothesizes that the intervention group will have greater improvement in CKD outcomes than the control group.
Description: Changes in systolic blood pressure between baseline and 12 months will be compared between the intervention group and control group.
Measure: Change in Systolic Blood Pressure between baseline and 12 months Time: Baseline, 12 monthsDescription: Changes in diastolic blood pressure between baseline and 12 months will be compared between the intervention group and control group.
Measure: Change in Diastolic Blood Pressure between baseline and 12 months Time: Baseline, 12 monthsDescription: BP will be collected at 4 time points - baseline, 1, 6, 12 months. This will be compared between the intervention group and control group.
Measure: Slope of systolic BP between baseline and 12 months using all available BP values Time: Baseline up to 12 monthsDescription: BP will be collected at 4 time points - baseline, 1, 6, 12 months. This will be compared between the intervention group and control group.
Measure: Slope of diastolic BP between baseline and 12 months using all available BP values Time: Baseline up to 12 monthsDescription: This is a 28-item questionnaire measuring objective CKD disease knowledge and includes questions about goals, cardiovascular risk, and anti-hypertensive medications. Patients will answer the questions with a yes or no answer and their score will be based on how many responses were correct. This number will be converted to a percentage.
Measure: CKD knowledge measured by the Kidney Knowledge Survey (KiKS) Time: Baseline up to 12 monthsDescription: This is a 13-item measure with the answers on a Likert scale of 1 (not at all sure) to 4 (extremely sure). The higher the score the higher the self-efficacy, with a range from 13-52.
Measure: Medication Adherence Self-Efficacy Scale-Revised (MASES-R) Time: Baseline up to 12 monthsDescription: This scale is to quantify adherence to pharmacological treatments by means of 8 items. Patients will answer yes or no to these items, where a no response = 1 point and a yes response = 0 points. Levels of adherence are based on the following scores: 3-8 = low adherence; 1-2 = medium adherence; 0 = high adherence.
Measure: Morisky Medication Adherence Scale (MMAS - 8) Time: Baseline up to 12 monthsDescription: Length of time provider spends with the patient. This will be compared between the intervention group and control group.
Measure: Visit Time with provider Time: Enrollment visit (baseline)Description: Length of time between patient check-in and check-out. This will be compared between the intervention group and control group.
Measure: Total time in clinic Time: Enrollment visit (baseline)Description: This contains a 17-item questionnaire in which the participants select scores from 1-7 or does not apply. A number of 1 = not at all and a score of 7 = considered very true, and zero = not applicable.
Measure: Patient Motivation by the Treatment Self-Regulation Questionnaire scale (TSRQ) Time: Baseline up to 12 monthsDescription: This is a 15-item questionnaire that assesses the quality of physician to patient communication completed by the patients. There are 5 answers to choose from; poor, fair, good, very good, and excellent. The Score range is 1-5, where 1 means negative perception of communication and 5 means positive perception of communication.
Measure: Satisfaction with CKD care based on Communication Assessment Tool (CAT) Time: Baseline up to 12 monthsDescription: This is a 21-item questionnaire that is completed by the patients, and select from the the 4 choices: very strongly agree, strongly agree, agree, and neutral/disagree. Each answer is worth one point on a Likert scale with a higher score meaning more satisfied.
Measure: Satisfaction with CKD care based on Consultation Care Measure (CCM) Time: Baseline up to 12 monthsDescription: During health coach phone calls, participants will be asked 37 questions about their perceptions of the health coach program, including how much their participation in CHECK-D helped participants change various behaviors. Participant responses will be used to examine various measures of reliability and validity during the analyses of data acquired though this survey.
Measure: Perceptions of health coaching for the intervention group Time: Baseline up to 12 monthsDescription: The EMR will be reviewed to evaluate the patients medication refills for adherence.
Measure: Medication adherence from the electronic medical record (EMR) Time: Baseline up to 12 monthsDescription: This is an 8-item scale regarding self-efficacy where each statement is rated on the level of agreement from 1-5. 1 is disagree and 5 is agree.
Measure: Self-efficacy for disease self-management based on The Perceived Kidney/Dialysis Self-Management Scale (PKDSMS) Time: Baseline up to 12 monthsDescription: This is a 5-item survey about knowledge and behaviors regarding sodium in the diet.
Measure: Self-reported Blood Pressure-Related Behaviors Survey Time: Baseline up to 12 monthsDescription: Provider adoption will be measured by the percentage of enrolled patients whose providers used the EDI with them during their visit. Data will be collected by EMR query and a 1-item question in the patient survey.
Measure: Provider Adoption based on EMR query and patient survey Time: BaselineDescription: Provider fidelity will be measured by the percentage of enrolled patients in the intervention clinics whose providers entered 1-2 patient specific goals in the EDI. This will be collected through EMR query.
Measure: Provider Fidelity measured by EMR query Time: BaselineDescription: Provider perception of usefulness will be measured by a survey of 2-3 questions about how useful they thought it was.
Measure: Provider Perception of Usefulness by provider survey Time: Baseline up to 12 monthsDescription: Change in Serum Creatinine between baseline and 12-months
Measure: Change in serum creatinine Time: Baseline, 12 monthsThere are currently no clinical studies reporting clinical characteristics difference between the hypertension patients with and without ACEI treatment when suffered with novel coronavirus infection in China.
Description: The percentage of patients admitted to the ICU at any time during the 28 days of onset COVID-19.
Measure: Occupancy rate in the intensive care unit (ICU) Time: up to 28 daysDescription: The number of patients requiring mechanical ventilation.
Measure: Mechanical Ventilation Time: up to 28 daysDescription: The number of patients who died of 2019-nCoV infection.
Measure: Death Time: up to 28 daysDescription: The number of died 2019-nCoV infected patients from any cause.
Measure: All cause mortality Time: up to 28 daysDescription: Time from onset of symptoms to admitted to the ICU, requiring mechanical ventilation, and death.
Measure: Time from onset of symptoms to main outcome and its components Time: up to 28 daysDescription: Time to Clinical Recovery
Measure: Time to Clinical Recovery Time: up to 28 daysThe study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.
Some studies have shown that the main pathogenesis of patients with covid19 is related to ACE2 receptor. Lung is one of the main organs, and there are many ACE2 receptors in cardiovascular system. ACEI / ARB is the main target of antihypertensive drugs. Previous reports suggested that there were large number of patients with covid19 also suffered from hypertension, suggesting that patients with hypertension may be the susceptible to covid19. Therefore, we try to follow up the patients admitted to Hankou hospital to explore the impact of hypertension and hypertension treatment on the severity and prognosis of patients with covid19, so as to provide new methods for the treatment of patients with covid19 in the future.
Description: mortality in 28-day
Measure: Rate of Death Time: From date of admission until the date of death from any cause, up to 60 daysDescription: evaluate the severity of pneumonia according to CT scans and clinical manifestation
Measure: the severity of pneumonia Time: From date of admission until the date of discharge or death from any cause, up to 60 daysDescription: days from admission to discharge or death
Measure: the length of hospital stay Time: From date of admission until the date of discharge or death from any cause, up to 60 daysCoronavirus disease 2019 (COVID-19) is a pandemic infection caused by a virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Because SARS-CoV-2 is known to require the angiotensin-converting enzyme 2 (ACE-2) receptor for uptake into the human body, there have been questions about whether medications that upregulate ACE-2 receptors might increase the risk of infection and subsequent complications. One such group of medications are anti-hypertensives that block the renin-angiotensin system, including both angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB). Both ACEi and ARB are widely used for the treatment of hypertension. Early reports from China and Italy suggest that many of those who die from COVID-19 have a coexisting history of hypertension. Consequently, there have been questions raised as to whether these 2 types of blood pressure medication might increase the risk of death among patients with COVID-19. However, it is well known that the prevalence of hypertension increases linearly with age. Therefore, it is possible that the high prevalence of hypertension and ACEi/ARB use among persons who die from COVID-19 is simply confounded by age (older people are at risk of both a history of hypertension and dying from COVID-19). Whether these commonly prescribed blood pressure medications increase the risk of COVID-19 or not remains unanswered. Statements from professional cardiology societies on both sides of the Atlantic have called for urgent research into this question. Our study aims to randomize patients with primary (essential) hypertension who are already taking ACEi/ARB to either switch to an alternative BP medication or continue with the ACEi/ARB that they have already been prescribed. Adults with compelling indications for ACEi/ARB will not be enrolled.
Description: Time from randomization to the first occurrence of any of the clinical events above
Measure: Number of Covid-19 positive participants who die, require intubation in ICU, or require hospitalization for non-invasive ventilation (NIV) Time: 12 monthsDescription: Time from randomization to the first occurrence of above
Measure: Number of Covid-19 positive participants who die Time: 12 monthsDescription: Time from randomization to the first occurrence of above
Measure: Number of Covid-19 positive participants who require intubation in intensive care unit (ICU) Time: 12 monthsDescription: Time from randomization to the first occurrence of above
Measure: Number of Covid-19 positive participants who require hospitalization for non-invasive ventilation (NIV) Time: 12 monthsDescription: Time from randomization to the first occurrence of above
Measure: Number of SARS-CoV-2 positive participants Time: 12 monthsDescription: Performed in a random sub-sample of the cohort (both study arms)
Measure: 24 hour mean systolic BP (mmHg) on ambulatory BP monitoring Time: 12 monthsDescription: Time from randomization to the first occurrence of above
Measure: All-cause mortality Time: 12 monthsMulticentric non-profit observational study, in patients with COVID-19 hospitalized in Italy, conducted through a pseudonymised survey.
Description: Using anamnestic data collected from the health record of the hospital or of the general practitioner, we will count the number of COVID-19 patients enrolled that were treated with ACE Inhibitors or ARB.
Measure: Numbers of COVID-19 patients enrolled that use ACE inhibitors and/or Angiotensin Receptor Blockers (ARB) as antihypertensive agents Time: 3 monthsDescription: This study want to observe whether the assumption of antihypertensive ACE inhibitors or ARB increases the severity of the clinical manifestation of COVID19
Measure: Numbers of COVID-19 patients enrolled with no symptoms, with moderate symptoms or with severe symptoms of pneumoni based on the WHO specification for ARDS that also used ACE inhibitors and/or Angiotensin Receptor Blockers (ARB) as antihypertensive agents Time: 3 monthsDescription: Collecting selected data from the health record and hospital charts of the patients we will assess whether among the recorded parameters there are any that can predict COVID19 prevalence and severity
Measure: Number and type of anthropometric and clinical parameters that associate with COVID19 and COVID-19 severity Time: 3 monthsIt is supposed to monitor hypertensive patients who are infected or have clinical manifestations of COVID-19 for 1 month after the onset of the disease. Three groups will be considered: 1. receiving ACE inhibitors 2. receiving ARBs 3. receiving DIR.
Description: BP one week before COVID-19 infection and 3 weeks follow-up after COVID-19 onset
Measure: BP (hypertensive efficacy) Time: 4 weeksDescription: features of disease course: number of patients and duration of fever (above 37.2C), duration of cough (days), duration of throat pain (days), headache (days), nausea or vomiting (days), diarrhea (days), myalgia or arthalgia (days), and numder of patients who need hospital and intensive care unit
Measure: COVID-19 course Time: 3 weeksHospitalized patients with COVID-19 will be included in the study in centers around Poland. After the hospitalization, a short questionnaire will be completed, including pre-hospitalization diagnoses, pre-hospitalization medications, clinical status on admission, the course, complication and the duration of hospitalization. The questionnaire will be available in paper form and on-line.
Description: Death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke
Measure: Adverse events Time: through study completion, an average of 2 weeksDescription: Number of participants with death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke analyzed separately for each of the endpoints
Measure: Number of participants with death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke Time: through study completion, an average of 2 weeksDescription: Ventilation during hospitalization
Measure: Ventilation during hospitalization Time: through study completion, an average of 2 weeksDescription: Number of participants with death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke analyzed separately for each of the endpoints
Measure: Number of participants with death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke Time: prolonged follow up, through study completion, an average of one yearBackground. Angiotensing converting enzyme type 2 (ACE2), a key enzyme of the renin-angiotensin-aldosterone system (RAAS), is the receptor of SARS-CoV-2 for cell entry into lungs. Because ACE2 may be modulated by RAAS inhibitors, such as angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARBs), there is concern that patients treated with ACEi and ARBs may be at higher risk for COVID-19 infection and severity. Aim. To analyze the associations between COVID-19 and hypertension, and treatments with ACEi and ARBs. Methods. In this retrospective observational study, consecutive patients hospitalized for suspected COVID-19 pneumonia will be divided into 2 groups, whether or not COVID-19 is confirmed. The two groups will be compared for baseline characteristics, mainly prior treatment with ACEi and ARBs, and clinical outcome at 1-month follow-up. The main hypothesis is that ACEi and ARBs, which interact differently with ACE2, may have different relationships with COVID-19 infection or severity.
Description: Prevalence of a previous treatment by angiotensin converting enzyme inhibitors in patients with and without confirmed Covid-19 pneumonia.
Measure: Prior treatment by ACEi Time: at admission to hospitalDescription: Prevalence of a previous treatment by angiotensin II type 1-receptor blockers in patients with and without confirmed Covid-19 pneumonia.
Measure: Prior treatment by ARB Time: at admission to hospitalDescription: Association between COVID-19 infection status and other baseline characteristics and comorbidities (age, sex, history of hypertension, chronic heart disease, diabetes mellitus, COPD, asthma, obesity, allergies)
Measure: Baseline characteristics and comorbidities Time: at admission to hospitalDescription: Association between previous treatment by ACEi and ARBs and clinical course of COVID-19 (one-month mortality, hospitalization in intensive care unit, duration of hospital stay, early discharge to home)
Measure: Major Clinical Adverse Events Time: One month follow-upThe current COVID-19 pandemic (caused by the SARS-CoV-2 virus) represents the biggest medical challenge in decades. Whilst COVID-19 mainly affects the lungs it also affects multiple organ systems, including the cardiovascular system. There are documented associations between severity of disease and risk of death and To provide all the information required by review bodies and research information systems, we ask a number of specific questions. This section invites you to give an overview using language comprehensible to lay reviewers and members of the public. Please read the guidance notes for advice on this section. 5 DRAFT Full Set of Project Data IRAS Version 5.13 advancing age, male sex and associated comorbid disease (hypertension, ischaemic heart disease, diabetes, obesity, COPD and cancer). The most common complications include cardiac dysrhythmia, cardiac injury, myocarditis, heart failure, pulmonary embolism and disseminated intravascular coagulation. It is thought that the mechanism of action of the virus involves binding to a host transmembrane enzyme (angiotensin- converting enzyme 2 (ACE2)) to enter some lung, heart and immune cells and cause further damage. While ACE2 is essential for viral invasion, it is unclear if the use of the common antihypertensive drugs ACE inhibitors or angiotensin receptor blockers (ARBs) alter prognosis. This study aims to look closely at the health of the vascular system of patients after being treated in hospital for COVID-19 (confirmed by PCR test) and compare them to patients who had a hospital admission for suspected COVID-19 (negative PCR test) . Information from this study is essential so that clinicians treating patients with high blood pressure understand the impact of the condition and these hypertension medicines in the context of the current COVID-19 pandemic. This will allow doctors to effectively treat and offer advice to patients currently prescribed these medications or who are newly diagnosed with hypertension.
Description: Ambulatory Blood Pressure Monitoring systolic blood pressure
Measure: ABPM systolic blood pressure Time: 24 hours (all day and night)Description: Ambulatory Blood Pressure Monitoring diastolic blood pressure
Measure: 24-hr ABPM DBP Time: 24 hours (all day and night)Description: Day Ambulatory Blood Pressure Monitoring systolic blood pressure
Measure: day ABPM SBP Time: 8am to 8pmDescription: Day Ambulatory Blood Pressure Monitoring diastolic blood pressure
Measure: day ABPM DBP Time: 8am to 8pmDescription: Night Ambulatory Blood Pressure Monitoring systolic blood pressure
Measure: night ABPM SBP Time: 8pm to 8amDescription: Night Ambulatory Blood Pressure Monitoring diastolic blood pressure
Measure: night ABPM DBP Time: 8pm to 8amDescription: The fall in pressure, called the "dip", is defined as the difference between daytime mean systolic pressure and nighttime mean systolic pressure expressed as a percentage of the day value
Measure: dipping status Time: 24 hours (all day and night)Description: he morning surge was defined as the difference between the mean systolic blood pressure during the 2 hours after waking and arising minus the mean systolic blood pressure during the hour that included the lowest blood pressure during sleep.
Measure: morning surge Time: 24 hours (all day and night)Description: 24 hour Ambulatory Blood Pressure Monitoring heart rate
Measure: 24 hour ABPM HR Time: 24hr (all day and night)Description: Day Ambulatory Blood Pressure Monitoring heart rate
Measure: day ABPM HR Time: 8 am to 8 pmDescription: Night Ambulatory Blood Pressure Monitoring heart rate
Measure: night ABPM HR Time: 8pm to 8 amIn Barbados, levels of hypertension are high (40.7%) and cause of a high proportion of deaths due to cardiovascular diseases. In this study, the Stanford University-led Chronic Disease Self-Management Program (CDSMP) will be modified to form one of the basic components of a three-pronged intervention to improve blood pressure control. Our overall goal is to evaluate the effectiveness of a hypertension self-management program in community-based settings. With the advent of the Coronavirus disease 2019 (COVID-19) we recognize that it may be necessary to adapt the programme to accommodate virtual delivery. Our specific aims are to: 1. Adapt the Stanford (CDSMP) to ensure cultural appropriateness to Barbados. In view of the need to adhere to physical distance guidelines in the era of COVID-19 disease, modifications will be made to enhance virtual delivery while maintaining programme fidelity. We will engage stakeholders in performing modifications related to content, context and mode of delivery of the CDSMP program with the goal of ensuring cultural appropriateness. 2. Determine the clinical effectiveness of CDSMP combined with medication enhancement tools. We will conduct a cluster randomized trial in twelve faith-based organizations(FBOs) in Barbados. We are primarily interested in studying the changes in systolic blood pressure. Secondarily, we will also assess change in weight, medication adherence, dietary behavior and physical activity. 3. Understand the barriers and facilitators to implementation and sustainability of CDSMP plus self-monitoring tools in faith-based organizations. We will assess cost and sustainability of the intervention and qualitatively assess factors associated with barriers and facilitators of implementation in FBOs in Barbados. Impact and novelty: We aim to increase the proportion of patients with controlled hypertension leading to reduced illness and deaths from strokes and heart attacks in particular. Few studies have looked at a blended approach to CDSMP delivery and these will become more necessary in the era of COVID-19. Findings on the factors impacting implementation will be transferable to small island developing states and other predominantly black populations.
Description: We will measure systolic blood pressure before and 6 months after the interventions
Measure: Systolic blood pressure Time: Six monthsDescription: We will measure participants' weight in kilograms before and six months after the intervention
Measure: Mean weight change for intervention and control groups Time: Six monthsDescription: Changes in dietary behavior will be monitored by using the Dietary Approaches to Stop Hypertension Accordance Score. Score ranges from 0 to 9. A low score represents a poor diet for hypertension control. The higher the score the more appropriate for hypertension control.
Measure: Level of adherence to the Dietary Approaches to Stop Hypertension (DASH) Diet Time: Six monthsDescription: Using the results of the GPAQ median physical activity in MET-minutes per week will be calculated before the intervention as well as six months post intervention
Measure: Assessing physical activity levels using the Global Physical Activity Questionnaire (GPAQ) Time: Six monthsDescription: Perceived self-efficacy scores will be calculated using a tool developed by K Lorig(Stanford University School of Medicine) for measuring self-efficacy in chronic disease management programs. Score ranges from 1 to 10. A higher score is better.
Measure: Self-Efficacy for Managing Chronic Diseases 6-item Scale Time: Six monthsThe virus infection Covid-19 fills our hospitals and intensive care departments in a very unique way and there is a lack of essential insight into the pathophysiology of the disease. As a result, very specific treatment options are missing. The US Medicines Agency (FDA) has in the last days given a general license for treatment with inhaled nitric oxide (iNO). Inhaled NO in Sweden (and Europe) is approved for the indication of pulmonary hypertension in adults. However, no one has yet described the occurrence of pulmonary hypertension, with or without right ventricular loading, in the Covid-19 patients who become so seriously ill that they need to be treated at an IVA ward. Knowledge of this is, of course, a prerequisite for determining the need for pulmonary artery catheterization (PA catheter, Swan-Ganz catheter) and also to better understand whether iNO treatment or other forms of lung selective vasodilation therapy may be of benefit to this patient group.
Description: To determine the prevalence of pulmonary hypertension and right ventricular load in patients with COVID-19 treated in intensive care unit evaluated by routine echocardiography.
Measure: Prevalence Time: Day 1Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for COVID-19, enters type II pneumocytes using angiotensin-converting enzyme 2 (ACE2). It is unclear whether ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) increase, decrease, or have no significant effect on ACE2 expression or activity. Therefore, ACEI and ARB may be harmful, beneficial, or have no impact on Coronavirus Disease 2019 severity and mortality. The Specific Aims of this observational study are: (1) Among SARS-CoV-2-positive outpatients, compare all-cause hospitalization and mortality rates between: 1.1 Current users of a range of doses of ACEI/ARB- vs. non- ACEI/ARB-based regimens, and 1.2 Current users of a range of doses of ACEI- vs. ARB-based regimens, and (2) Among those hospitalized for COVID-19, compare all-cause mortality between: 2.1 Current users of a range of doses of ACEI/ARB- vs. non- ACEI/ARB-based regimens, and 2.2 Current users of a range of doses of ACEI- vs. ARB-based regimens.
Description: For outpatient Veterans with a positive SARS-CoV-2 test (Aims 1.1 and 1.2), the primary outcome is a composite of time to all-cause hospitalization or all-cause mortality.
Measure: All-Cause-Hospitalization or All-Cause Mortality Time: Through study completion (approximately July 31, 2020).Description: For Veterans hospitalized with COVID-19 (Aims 2.1 and 2.2), the primary outcome is time to all-cause mortality.
Measure: All-Cause Mortality Time: Through study completion (approximately July 31, 2020).Description: For aims 1 and 2, a secondary outcome will be time to intensive care unit (ICU) admission.
Measure: ICU admission Time: Through study completion (approximately July 31, 2020).Description: For aims 1 and 2, a secondary outcome will be duration of hospitalization.
Measure: Duration of hospitalization Time: Through study completion (approximately July 31, 2020).Description: For aim 2, a secondary outcome will be time to mechanical ventilation.
Measure: Mechanical ventilation Time: Through study completion (approximately July 31, 2020).Description: For aim 2, a secondary outcome will be time to in-hospital dialysis.
Measure: Dialysis Time: Through study completion (approximately July 31, 2020).Description: Time to gastrointestinal bleed. This will be a negative control outcome.
Measure: Gastrointestinal bleed Time: Through study completion (approximately July 31, 2020).Description: Time to urinary tract infection. This will be a negative control outcome.
Measure: Urinary tract infection Time: Through study completion (approximately July 31, 2020).